Article

Pregnancy outcome following gestational exposure to venlafaxine: A multicenter prospective controlled study

The Motherisk Program, The Hospital for Sick Children, University of Toronto, Ontario, Canada.
American Journal of Psychiatry (Impact Factor: 13.56). 11/2001; 158(10):1728-30. DOI: 10.1176/appi.ajp.158.10.1728
Source: PubMed

ABSTRACT Because there are no studies available on the safety of venlafaxine during pregnancy, the authors' goal in this study was to determine whether venlafaxine increases the risk for major malformations.
Data on 150 women exposed to venlafaxine during pregnancy in seven pregnancy counseling centers were compared with data from studies of pregnant women who 1) received selective serotonin reuptake inhibitor antidepressants (SSRIs) (N=150) and 2) who received nonteratogenic drugs (N=150).
Among the 150 women who were exposed to venlafaxine during pregnancy, 125 had live births, 18 had spontaneous abortions, and seven had therapeutic abortions; two of the babies had major malformations. There were no significant differences between these women and the two comparison groups on any of the measures analyzed.
These results suggest that the use of venlafaxine during pregnancy does not increase the rates of major malformations above the baseline rate of 1%-3%.

0 Bookmarks
 · 
99 Views
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: In pregnant women with major depression, the overarching goal of treatment is to achieve or maintain maternal euthymia, thus limiting both maternal and fetal exposure to the harmful effects of untreated or incompletely treated depression. However, the absence of uniformly effective therapies with guaranteed obstetric and fetal safety makes the treatment of major depression during pregnancy among the most formidable of clinical challenges. Clinicians and patients are still faced with conflicting data and expert opinion regarding the reproductive safety of antidepressants in pregnancy, as well as large gaps in our understanding of the effectiveness of most antidepressants and nonpharmacological alternatives for treating antenatal depression. In this paper, we provide a clinically focused review of the available information on potential maternal and fetal risks of untreated maternal depression during pregnancy, the effectiveness of interventions for maternal depression during pregnancy, and potential obstetric, fetal, and neonatal risks associated with antenatal antidepressant use.
    Drug, Healthcare and Patient Safety 09/2014; 6:109-29. DOI:10.2147/DHPS.S43308
    This article is viewable in ResearchGate's enriched format
  • [Show abstract] [Hide abstract]
    ABSTRACT: ZET: Dikkat çekici bir konu: Hamile ve depresyondaki kadınlara ilaç önerilmeli mi? Erkeklere kıyasla kadınlar daha fazla depresyon yaygınlık oranlarına sahiptir ve özellkle doğurganlık çağında dep-resyona daha da duyarlıdırlar. Depresyon oranları gebelik dönemindeki kadınlar için %20'lere kadar ulaşabilir. Aslında kadınları tedavi eden bir klinisyenin, kendisini annenin ve bebeğin gelişiminin korunması için en uygun yöntemi seçmeye çalışırken bulması oldukça muhtemeldir. Emniyet konuları ve doğumla ilgili olumsuz sonuçlar gebelikte anti-depresan kullanımı ile ilgili başlıca endişe alanlarıdır. Diğer taraftan, tedavi edilmemiş depresyon da anne ve bebek için sağlık komplikasyonlarına yol açma potansiyeline sahiptir. Ancak gebelikte antidepresan kullanımının muh-temel yan etkilerinin daha fazla vurgulandığı ama tedavi edilmemiş depresyonun o kadar önemsenmediği aşikardır. Halihazırdaki çalışmalar gebelik sırasında antidepresan kul-lanımının emniyetli olup olmadığına dair çelişkili sonuçlar ortaya koymaktadır dolayısıyla da mevcut verilerin yorum-lanması çok dikkatli bir şekilde yapılmalıdır. Ebeveynlerle birlikte karar verirken her iki seçeneğin de riskleri ve fay-daları göz önüne alınmalıdır. Anahtar sözcükler: Gebelik, antidepresan emniyeti, tera-tojenite, tedavi edilmemiş depresyon Journal of Mood Disorders 2011;1(3):118-25 ABS TRACT: A challenging issue: Should medications be prescribed to pregnant and depressed women? Women have higher prevalence rates of depression than men and they are particularly vulnerable to depression in childbearing years. The rates of depression can reach up to 20% of all women during pregnancy. Actually, physicians who treat women are likely to find themselves trying to choose the best option for protection of the mother and for the development of her child. Safety issues and negative birth outcomes are matters of concern with antidepressant use during pregnancy. Otherwise, untreated depression also has potential to cause health complications for both mother and infant. It is obvious that possible adverse effects of antidepressant use during pregnancy are more emphasized but adverse outcomes of untreated depression are underrated. Currently, studies exhibit conflicting results about antidepressant safety in pregnancy period so current data must be cautiously interpreted. The risks and benefits of both options must be taken into account in decision-making process with families. Ya zış ma Ad re si / Add ress rep rint re qu ests to: Elekt ro nik pos ta ad re si / E-ma il add ress: nmda25@gmail.com Ka bul ta ri hi / Da te of ac cep tan ce: 2 Eylül 2011 / September 2, 2011 Bağıntı beyanı: N.A., E.O., M.G.: Yazarlar bu makale ile ilgili olarak herhangi bir çıkar çatışması bildirmemişlerdir..: The authors reported no conflict of interest related to this article.
    09/2011; 1(3):118-25. DOI:10.5455/jmood.20110902072926